Galderma's Nemluvio Shows Sustained Efficacy in Prurigo Nodularis Over Three Years
Event summary
- Galderma's Nemluvio demonstrated long-term disease control in prurigo nodularis patients for up to three years, per OLYMPIA open-label extension study data.
- Over 70% of patients achieved clear or almost clear skin lesions, and over 85% saw more than 75% healed lesions based on prurigo activity score.
- Nemluvio maintained a consistent safety profile with no new significant adverse effects reported.
The big picture
Galderma's Nemluvio is the first approved monoclonal antibody targeting IL-31 receptor alpha, addressing a significant unmet need in prurigo nodularis. The long-term efficacy data strengthens its position in the dermatology market, particularly as chronic itch conditions gain more attention from regulators and payers. With approvals already secured in key markets like the U.S. and EU, Galderma is well-positioned to capitalize on this growing therapeutic segment.
What we're watching
- Market Expansion
- Whether Galderma can leverage these long-term efficacy data to expand Nemluvio's market share in prurigo nodularis and atopic dermatitis.
- Regulatory Dynamics
- The pace at which additional regulatory approvals for Nemluvio will be secured in other regions, given its growing clinical evidence base.
- Competitive Positioning
- How these results position Nemluvio against emerging therapies targeting similar neuroimmune pathways in chronic itch conditions.